A Phase 2 interventional study of Voriconazole and Voriconazole in Aspergillosis, Aspergilloma, sponsored by Pfizer. Completed at 6 sites in Japan. Open to participants aged 2 Years to 15 Years. Per ClinicalTrials.gov, last updated 2014-05-09.
Sponsored by Pfizer · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing voriconazole in Aspergillosis — none open to participants now, none under way, none of them phase 3. Voriconazole · Aspergillosis.
Among the 17 studies testing voriconazole in Aspergillosis, this one is the 10th largest by enrollment, is one of 2 that started in 2011, is one of 4 in phase 2, and was the 13th registered.
134 studies on the registry are indexed under Aspergillosis; 10 are open to participants now.
Browse Aspergillosis studies →None of the 17 studies testing voriconazole in Aspergillosis is open now. The open studies under Aspergillosis, anywhere →
Voriconazole: first FDA approval 2002 (VFEND), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 8 Aspergillosis studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 2 Years to 15 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 6 · Phase 4 4
First in 1997; this study’s year is marked. 2 started in 2011.
This study's enrollment of 21 is below the median of 47 across 75 interventional studies indexed under Aspergillosis.
Median enrollment 24 across the 17 interventional studies. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 17 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
11 studies in Aspergillosis by Pfizer: none open now, none under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 11 studies in Aspergillosis by Pfizer, this one is the only one that started in 2011, is the only one in phase 2, and was the 10th registered.
Pfizer’s Aspergillosis studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing voriconazole in Aspergillosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 11 in Aspergillosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In this study we will measure the concentration of the drug called voriconazole which is used to fight infections caused by fungus in children who usually are cancer patients and have their immune system down. Since we know the dose in adults, and we think we know the matching doses in the young patients ages 2 to less than 15 years old, we will compare the amount of drug that goes into the system with what we know works in adults. We give the drug by a needle directly into the blood, then few days later we stop that and give the drug by mouth. Meanwhile, we draw a little bit of blood at certain times to measure the drug in it.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunocompromised children aged 2 to \<15 and 12 to \<15 years weighing \<50 kg who are at high risk for systemic fungal infection.
Drug: Voriconazole
Immunocompromised children aged 12 to \<15 years weighing more than 50 kg who are at high risk for systemic fungal infection.
Drug: Voriconazole
Study Days 1: IV voriconazole 9 mg/kg q12h. Study Days 2 to 7: IV voriconazole 8 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 9 mg/kg q12h with a maximum of 350 mg q12 h. Notes: If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose. Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30. (IV = Intravenous; POS = Powder for oral suspension)
Also known as: UK-109,496; Vfend; Voriconazole
Study Days 1: IV voriconazole 6 mg/kg q12h. Study Days 2 to 7: IV voriconazole 4 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h. Notes: If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose. Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30. (IV = Intravenous; POS = Powder for oral suspension)
Also known as: UK-109,496; Vfend; Voriconazole
Area Under the Plasma Concentration-time Profile From Time Zero to Twelve Hours at Steady-State (AUC12,ss) Following IV Administration
AUC12,ss was obtained by the Linear/Log trapezoidal method.
Time frame: Day 7 (up to Day 20): predose, 1 hour after the start of infusion, 10-20 minutes after the end of infusion, and 4, 6, 8, and 12 hours after the start of infusion
Maximum Observed Plasma Concentration at Steady State (Cmax,ss) Following IV Administration
Time frame: Day 7 (up to Day 20): predose, 1 hour after the start of infusion, 10-20 minutes after the end of infusion, and 4, 6, 8, and 12 hours after the start of infusion
Time to Reach Maximum Observed Plasma Concentration (Tmax) Following IV Administration
Time frame: Day 7 (up to Day 20): predose, 1 hour after the start of infusion, 10-20 minutes after the end of infusion, and 4, 6, 8, and 12 hours after the start of infusion
Area Under the Plasma Concentration-time Profile From Time Zero to Twelve Hours at Steady-State (AUC12,ss) Following Oral Administration
AUC12,ss was obtained by the Linear/Log trapezoidal method.
Time frame: Day 14 (the 7th day of oral treatment) or later: predose, and 1, 2, 4, 6, 8, and 12 hours after dosing
Maximum Observed Plasma Concentration at Steady State (Cmax,ss) Following Oral Administration
Time frame: Day 14 (the 7th day of oral treatment) or later: predose, and 1, 2, 4, 6, 8, and 12 hours after dosing
Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Oral Administration
Time frame: Day 14 (the 7th day of oral treatment) or later: predose, and 1, 2, 4, 6, 8, and 12 hours after dosing
Number of Participants Assessed Near Distance Visual Acuity Test
Time frame: Screening, Day 7 (the 7th day of IV treatment), Day 8 (the 1st day of oral treatment), Day 14 (the 7th day of oral treatment), and the 30-day follow-up visit
Number of Participants Assessed Color Vision Test
Time frame: Screening, Day 7 (the 7th day of IV treatment), Day 8 (the 1st day of oral treatment), Day 14 (the 7th day of oral treatment), and the 30-day follow-up visit
Number of Participants Assessed Visual Questionnaire
Time frame: Screening, Day 7 (the 7th day of IV treatment), Day 8 (the 1st day of oral treatment), Day 14 (the 7th day of oral treatment), and the 30-day follow-up visit
Ratio of AUC12,ss Following IV Administration Relative to AUC12,ss Following Oral Administration
Ratio was calculated from the following formula; AUC12,ss Following Oral Administration over AUC12,ss Following IV Administration
Time frame: AUC12, ss for IV:Day 7 (up to Day 20): predose, 1 hour after the start of infusion, 10-20 minutes after the end of infusion. AUC12,ss for oral: Day 14 (the 7th day of oral treatment) or later: predose, and 1, 2, 4, 6, 8, and 12 hours after dosing.
Area Under the Plasma Concentration-time Profile From Time Zero to Twelve Hours at Steady-State (AUC12,ss) of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration
AUC12,ss was obtained by the Linear/Log trapezoidal method.
Time frame: Day 7 (up to Day 20): predose, 1 hour after the start of infusion, 10-20 minutes after the end of infusion, and 4, 6, 8, and 12 hours after the start of infusion
Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration
Time frame: Day 7 (up to Day 20): predose, 1 hour after the start of infusion, 10-20 minutes after the end of infusion, and 4, 6, 8, and 12 hours after the start of infusion
Time to Reach Maximum Observed Plasma Concentration (Tmax) of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration
Time frame: Day 7 (up to Day 20): predose, 1 hour after the start of infusion, 10-20 minutes after the end of infusion, and 4, 6, 8, and 12 hours after the start of infusion
Area Under the Plasma Concentration-time Profile From Time Zero to Twelve Hours at Steady-State (AUC12,ss) of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration
AUC12,ss was obtained by the Linear/Log trapezoidal method.
Time frame: Day 14 (the 7th day of oral treatment) or later: predose, and 1, 2, 4, 6, 8, and 12 hours after dosing
Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration
Time frame: Day 14 (the 7th day of oral treatment) or later: predose, and 1, 2, 4, 6, 8, and 12 hours after dosing
Time to Reach Maximum Observed Plasma Concentration (Tmax) of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration
Time frame: Day 14 (the 7th day of oral treatment) or later: predose, and 1, 2, 4, 6, 8, and 12 hours after dosing
| Milestone | Participants Aged 2 to <12 Years | Participants Aged 12 to<15 Years and Weighed <50 kg | Participants Aged 12 to<15 Years and Weighed ≥50 kg |
|---|---|---|---|
| Started | 15 | 4 | 2 |
| Completed | 12 | 3 | 1 |
| Not completed | 3 | 1 | 1 |
| Withdrew: Adverse event | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Withdrew: Marketed voriconazole in post-therapy | 2 | 0 | 0 |
AUC12,ss was obtained by the Linear/Log trapezoidal method.
| μg*h/mL | Participants Aged 2 to <12 Years | Participants Aged 12 to<15 Years and Weighed <50 kg | Participants Aged 12 to<15 Years and Weighed ≥50 kg |
|---|---|---|---|
| Area Under the Plasma Concentration-time Profile From Time Zero to Twelve Hours at Steady-State (AUC12,ss) Following IV Administration | 51.92 ± 51 | 83.39 ± 56 | 17.27 ± 28 |
| mcg/mL | Participants Aged 2 to <12 Years | Participants Aged 12 to<15 Years and Weighed <50 kg | Participants Aged 12 to<15 Years and Weighed ≥50 kg |
|---|---|---|---|
| Maximum Observed Plasma Concentration at Steady State (Cmax,ss) Following IV Administration | 7.753 ± 38 | 9.233 ± 55 | 3.092 ± 42 |
| hrs | Participants Aged 2 to <12 Years | Participants Aged 12 to<15 Years and Weighed <50 kg | Participants Aged 12 to<15 Years and Weighed ≥50 kg |
|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) Following IV Administration | 2.96 (0.950 to 4.00) | 4.00 (2.92 to 4.20) | 1.34 (1.00 to 1.67) |
AUC12,ss was obtained by the Linear/Log trapezoidal method.
| μg*h/mL | Participants Aged 2 to <12 Years | Participants Aged 12 to<15 Years and Weighed <50 kg | Participants Aged 12 to<15 Years and Weighed ≥50 kg |
|---|---|---|---|
| Area Under the Plasma Concentration-time Profile From Time Zero to Twelve Hours at Steady-State (AUC12,ss) Following Oral Administration | 48.23 ± 83 | 59.42 ± 67 | 10.00 ± NA |
| mcg/mL | Participants Aged 2 to <12 Years | Participants Aged 12 to<15 Years and Weighed <50 kg | Participants Aged 12 to<15 Years and Weighed ≥50 kg |
|---|---|---|---|
| Maximum Observed Plasma Concentration at Steady State (Cmax,ss) Following Oral Administration | 7.755 ± 50 | 7.910 ± 45 | 2.030 ± NA |
| hrs | Participants Aged 2 to <12 Years | Participants Aged 12 to<15 Years and Weighed <50 kg | Participants Aged 12 to<15 Years and Weighed ≥50 kg |
|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) Following Oral Administration | 1.09 (0.917 to 3.78) | 1.00 (0.950 to 2.03) | 1.00 (1.00 to 1.00) |
| participants | All Participants |
|---|---|
| Screening | 18 |
| The 7th day of IV treatment | 18 |
| The 1st day of oral treatment | 17 |
| The 7th day of oral treatment | 15 |
| The 30 day follow up visit | 14 |
| participants | All Participants |
|---|---|
| Screening | 19 |
| The 7th day of IV treatment | 18 |
| The 1st day of oral treatment | 17 |
| The 7th day of oral treatment | 15 |
| The 30 day follow up visit | 14 |
| participants | All Participants |
|---|---|
| Screening | 19 |
| The 7th day of IV treatment | 18 |
| The 1st day of oral treatment | 17 |
| The 7th day of oral treatment | 15 |
| The 30 day follow up visit | 14 |
Ratio was calculated from the following formula; AUC12,ss Following Oral Administration over AUC12,ss Following IV Administration
| ratio | Participants Aged 2 to <12 Years | Participants Aged 12 to<15 Years and Weighed <50 kg | Participants Aged 12 to<15 Years and Weighed ≥50 kg |
|---|---|---|---|
| Ratio of AUC12,ss Following IV Administration Relative to AUC12,ss Following Oral Administration | 1.077 ± 0.547 | 0.648 ± 0.015 | 0.476 ± NA |
AUC12,ss was obtained by the Linear/Log trapezoidal method.
| μg*h/mL | Participants Aged 2 to <12 Years | Participants Aged 12 to<15 Years and Weighed <50 kg | Participants Aged 12 to<15 Years and Weighed ≥50 kg |
|---|---|---|---|
| Area Under the Plasma Concentration-time Profile From Time Zero to Twelve Hours at Steady-State (AUC12,ss) of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration | 66.50 ± 30 | 80.99 ± 41 | 40.00 ± 2 |
| mcg/mL | Participants Aged 2 to <12 Years | Participants Aged 12 to<15 Years and Weighed <50 kg | Participants Aged 12 to<15 Years and Weighed ≥50 kg |
|---|---|---|---|
| Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration | 6.381 ± 28 | 8.066 ± 34 | 3.835 ± 1 |
| hrs | Participants Aged 2 to <12 Years | Participants Aged 12 to<15 Years and Weighed <50 kg | Participants Aged 12 to<15 Years and Weighed ≥50 kg |
|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration | 5.05 (2.87 to 11.8) | 4.49 (1.00 to 11.1) | 3.84 (1.67 to 6.00) |
AUC12,ss was obtained by the Linear/Log trapezoidal method.
| μg*h/mL | Participants Aged 2 to <12 Years | Participants Aged 12 to<15 Years and Weighed <50 kg | Participants Aged 12 to<15 Years and Weighed ≥50 kg |
|---|---|---|---|
| Area Under the Plasma Concentration-time Profile From Time Zero to Twelve Hours at Steady-State (AUC12,ss) of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration | 79.86 ± 36 | 90.84 ± 19 | 34.40 ± NA |
| mcg/mL | Participants Aged 2 to <12 Years | Participants Aged 12 to<15 Years and Weighed <50 kg | Participants Aged 12 to<15 Years and Weighed ≥50 kg |
|---|---|---|---|
| Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration | 7.971 ± 31 | 8.912 ± 22 | 3.720 ± NA |
| hrs | Participants Aged 2 to <12 Years | Participants Aged 12 to<15 Years and Weighed <50 kg | Participants Aged 12 to<15 Years and Weighed ≥50 kg |
|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration | 2.07 (0.000 to 7.78) | 2.03 (0.950 to 4.00) | 3.80 (3.80 to 3.80) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Participants Aged 2 to <12 Years | — | 0/15 (0%) | 13/15 (86.7%) |
| Participants Aged 12 to<15 Years and Weighed <50 kg | — | 0/4 (0%) | 4/4 (100%) |
| Participants Aged 12 to<15 Years and Weighed ≥50 kg | — | 0/2 (0%) | 1/2 (50%) |
| Event | Participants Aged 2 to <12 Years | Participants Aged 12 to<15 Years and Weighed <50 kg | Participants Aged 12 to<15 Years and Weighed ≥50 kg |
|---|---|---|---|
| PhotophobiaEye disorders | 5/15 | 3/4 | 1/2 |
| Febrile neutropeniaBlood and lymphatic system disorders | 10/15 | 2/4 | 1/2 |
| Anorectal disorderGastrointestinal disorders | 0/15 | 0/4 | 1/2 |
| Alanine aminotransferase increasedInvestigations | 1/15 | 2/4 | 0/2 |
| Aspartate aminotransferase increasedInvestigations | 1/15 | 2/4 | 0/2 |
| RashSkin and subcutaneous tissue disorders | 3/15 | 0/4 | 1/2 |
| ChromatopsiaEye disorders | 0/15 | 1/4 | 0/2 |
| ConjunctivitisEye disorders | 0/15 | 1/4 | 0/2 |
| KeratitisEye disorders | 0/15 | 1/4 | 0/2 |
| Vision blurredEye disorders | 0/15 | 1/4 | 0/2 |
| Age, Continuous(years) | Participants Aged 2 to <12 Years | Participants Aged 12 to<15 Years and Weighed <50 kg | Participants Aged 12 to<15 Years and Weighed ≥50 kg | Total |
|---|---|---|---|---|
| Mean | 7.7 ± 2.8 | 12.5 ± 0.6 | 14.0 ± 0.0 | 9.2 ± 3.4 |
| Sex: Female, Male(Participants) | Participants Aged 2 to <12 Years | Participants Aged 12 to<15 Years and Weighed <50 kg | Participants Aged 12 to<15 Years and Weighed ≥50 kg | Total |
|---|---|---|---|---|
| Female | 9 | 2 | 1 | 12 |
| Male | 6 | 2 | 1 | 9 |
The record gives a start of Sep 2011, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.
Results were first posted in May 2014, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Voriconazole